Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Operations (2020 - 2025)

Journey Medical (DERM) has disclosed Cash from Operations for 6 consecutive years, with 2383000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 105.96% year-over-year to 2383000.0, compared with a TTM value of 3932000.0 through Sep 2025, up 85.89%, and an annual FY2024 reading of 9127000.0, down 274.18% over the prior year.
  • Cash from Operations was 2383000.0 for Q3 2025 at Journey Medical, down from 942000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 18747000.0 in Q3 2023 and bottomed at 16520000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 1355736.84, with a median of 2383000.0 recorded in 2025.
  • The sharpest move saw Cash from Operations skyrocketed 357.44% in 2023, then plummeted 425.0% in 2024.
  • Year by year, Cash from Operations stood at 3206000.0 in 2021, then dropped by 19.65% to 3836000.0 in 2022, then plummeted by 330.66% to 16520000.0 in 2023, then surged by 113.47% to 2225000.0 in 2024, then plummeted by 207.1% to 2383000.0 in 2025.
  • Business Quant data shows Cash from Operations for DERM at 2383000.0 in Q3 2025, 942000.0 in Q2 2025, and 2832000.0 in Q1 2025.